Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study by K. Nakanishi, N. Sugimoto, Y. Kodera, H. Kawakami, A. Makiyama, H. Konishi, S. Morita, Y. Narita, K. Minashi, M. Imano, R. Inamoto, T. Nishina, T. Kawakami, M. Hagiwara, H. Kume, K. Yamaguchi, W. Hashimoto, K. Muro

Get full text